Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Jul;112(3):855–860. doi: 10.1111/j.1476-5381.1994.tb13158.x

Covariation of alpha 2-adrenoceptor density and function following irreversible antagonism with EEDQ.

M J Durcan 1, P F Morgan 1, M L Van Etten 1, M Linnoila 1
PMCID: PMC1910204  PMID: 7921612

Abstract

1. Administration of the irreversible antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, (EEDQ, 2 mg kg-1, i.p.) to mice reduced binding of [3H]-RX 821002 (2-methoxy-idazoxan) to alpha 2-adrenoceptors in whole mouse brain by 75% 24 h later. The receptor binding returned over time only being reduced by 25% by 16 days post administration; the time taken for binding to return to 50% of control levels was estimated to be 5.25 days. 2. EEDQ administration also resulted in the loss of the sedative effect of the alpha 2-adrenoceptor agonist, medetomidine, measured by the holeboard test of directed exploration and locomotor activity. Agonist-induced sedation returned to control values by 8 days post EEDQ administration. 3. EEDQ administration also resulted in the loss of the hypothermic response to medetomidine (0.1 mg kg-1, i.p.). Medetomidine-induced hypothermia returned to control values by 12 days post EEDQ administration. 4. Pretreatment with the selective alpha 2-adrenoceptor antagonist, RX 821002 (0.1-3.0 mg kg-1, i.p.) 45 min before EEDQ prevented the loss of alpha 2-adrenoceptors as well as the blockade of medetomide-induced sedation and hypothermia by EEDQ. 5. The results of these experiments indicate that there is significant receptor reserve for alpha 2-adrenoceptor-mediated behavioural and physiological responses.

Full text

PDF
855

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler C. H., Meller E., Goldstein M. Receptor reserve at the alpha-2 adrenergic receptor in the rat cerebral cortex. J Pharmacol Exp Ther. 1987 Feb;240(2):508–515. [PubMed] [Google Scholar]
  2. Adler C. H., Meller E., Goldstein M. Recovery of alpha 2-adrenoceptor binding and function after irreversible inactivation by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Eur J Pharmacol. 1985 Oct 8;116(1-2):175–178. doi: 10.1016/0014-2999(85)90200-6. [DOI] [PubMed] [Google Scholar]
  3. Agneter E., Drobny H., Singer E. A. Central alpha 2-autoreceptors: agonist dissociation constants and recovery after irreversible inactivation. Br J Pharmacol. 1993 Feb;108(2):370–375. doi: 10.1111/j.1476-5381.1993.tb12811.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Barturen F., Garcia-Sevilla J. A. Long term treatment with desipramine increases the turnover of alpha 2-adrenoceptors in the rat brain. Mol Pharmacol. 1992 Nov;42(5):846–855. [PubMed] [Google Scholar]
  5. Belleau B., DiTullio V., Godin D. The mechanism of irreversible adrenergic blockade by N-carbethoxydihydroquinolines--model studies with typical serine hydrolases. Biochem Pharmacol. 1969 May;18(5):1039–1044. doi: 10.1016/0006-2952(69)90107-5. [DOI] [PubMed] [Google Scholar]
  6. Belleau B., Martel R., Lacasse G., Ménard M., Weinberg N. L., Perron Y. G. N-carboxylic acid esters of 1,2- and 1,4-dihydroquinolines. A new class of irreversible inactivators of the catecholamine alpha receptors and potent central nervous system depressants. J Am Chem Soc. 1968 Jan 31;90(3):823–824. doi: 10.1021/ja01005a067. [DOI] [PubMed] [Google Scholar]
  7. Bousquet P., Feldman J., Tibirica E., Bricca G., Molines A., Dontenwill M., Belcourt A. New concepts on the central regulation of blood pressure. Alpha 2-adrenoceptors and "imidazoline receptors". Am J Med. 1989 Sep 18;87(3C):10S–13S. doi: 10.1016/0002-9343(89)90498-1. [DOI] [PubMed] [Google Scholar]
  8. Cox R. F., Waszczak B. L. Irreversible receptor inactivation reveals differences in dopamine receptor reserve between A9 and A10 dopamine systems: an electrophysiological analysis. Brain Res. 1990 Nov 26;534(1-2):273–282. doi: 10.1016/0006-8993(90)90139-3. [DOI] [PubMed] [Google Scholar]
  9. Crocker A. D., Cameron D. L. Receptor alkylating agents: novel tools for the study of receptor function in the central nervous system of the rat. Clin Exp Pharmacol Physiol. 1989 Jun;16(6):545–548. doi: 10.1111/j.1440-1681.1989.tb01603.x. [DOI] [PubMed] [Google Scholar]
  10. Durcan M. J., Lister R. G., Linnoila M. Interactions of alpha 2-adrenoceptor antagonists with medetomidine and with ethanol in a holeboard test. Neuropharmacology. 1989 Mar;28(3):275–281. doi: 10.1016/0028-3908(89)90104-4. [DOI] [PubMed] [Google Scholar]
  11. Giorgi O., Pibiri M. G., Biggio G. Differential turnover rates of D1 dopamine receptors in the retina and in distinct areas of the rat brain. J Neurochem. 1991 Sep;57(3):754–759. doi: 10.1111/j.1471-4159.1991.tb08216.x. [DOI] [PubMed] [Google Scholar]
  12. Hamblin M. W., Creese I. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline. Life Sci. 1983 May 9;32(19):2247–2255. doi: 10.1016/0024-3205(83)90423-x. [DOI] [PubMed] [Google Scholar]
  13. Langin D., Paris H., Dauzats M., Lafontan M. Discrimination between alpha 2-adrenoceptors and [3H]idazoxan-labelled non-adrenergic sites in rabbit white fat cells. Eur J Pharmacol. 1990 Apr 25;188(4-5):261–272. doi: 10.1016/0922-4106(90)90010-u. [DOI] [PubMed] [Google Scholar]
  14. Langin D., Paris H., Lafontan M. Binding of [3H]idazoxan and of its methoxy derivative [3H] RX821002 in human fat cells: [3H]idazoxan but not [3H] RX821002 labels additional non-alpha 2-adrenergic binding sites. Mol Pharmacol. 1990 Jun;37(6):876–885. [PubMed] [Google Scholar]
  15. Lehmann J., Koenig-Bérard E., Vitou P. The imidazoline-preferring receptor. Life Sci. 1989;45(18):1609–1615. doi: 10.1016/0024-3205(89)90270-1. [DOI] [PubMed] [Google Scholar]
  16. Meller E., Bohmaker K., Goldstein M., Friedhoff A. J. Inactivation of D1 and D2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J Pharmacol Exp Ther. 1985 Jun;233(3):656–662. [PubMed] [Google Scholar]
  17. Meller E., Goldstein M., Friedhoff A. J., Schweitzer J. W. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ): a new tool to probe CNS receptor function. Adv Exp Med Biol. 1988;235:121–136. doi: 10.1007/978-1-4899-2723-1_8. [DOI] [PubMed] [Google Scholar]
  18. Michel M. C., Insel P. A. Are there multiple imidazoline binding sites? Trends Pharmacol Sci. 1989 Sep;10(9):342–344. doi: 10.1016/0165-6147(89)90002-3. [DOI] [PubMed] [Google Scholar]
  19. Miralles A., Ribas C., Olmos G., García-Sevilla J. A. Differential effects of the alkylating agent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on brain alpha 2-adrenoceptors and I2-imidazoline sites in vitro and in vivo. J Neurochem. 1993 Nov;61(5):1602–1610. doi: 10.1111/j.1471-4159.1993.tb09793.x. [DOI] [PubMed] [Google Scholar]
  20. Olmos G., Miralles A., Barturen F., Garcia-Sevilla J. A. Characterization of brain imidazoline receptors in normotensive and hypertensive rats: differential regulation by chronic imidazoline drug treatment. J Pharmacol Exp Ther. 1992 Mar;260(3):1000–1007. [PubMed] [Google Scholar]
  21. Pilc A., Nowak G., Zak J. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline, an irreversible receptor inactivator, as a tool for measurement of alpha 2-adrenoceptor occupancy in vivo. Eur J Pharmacol. 1992 Feb 25;212(1):109–111. doi: 10.1016/0014-2999(92)90081-e. [DOI] [PubMed] [Google Scholar]
  22. Pilc A., Vetulani J., Nomura S., Enna S. J. An in vivo procedure for the selective inactivation of rat brain cerebral cortical alpha-adrenoceptors using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Brain Res. 1989 Jul 24;493(1):8–13. doi: 10.1016/0006-8993(89)90994-3. [DOI] [PubMed] [Google Scholar]
  23. Saller C. F., Kreamer L. D., Adamovage L. A., Salama A. I. Dopamine receptor occupancy in vivo: measurement using N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Life Sci. 1989;45(10):917–929. doi: 10.1016/0024-3205(89)90206-3. [DOI] [PubMed] [Google Scholar]
  24. Stillings M. R., Chapleo C. B., Butler R. C., Davis J. A., England C. D., Myers M., Myers P. L., Tweddle N., Welbourn A. P., Doxey J. C. Alpha-adrenoreceptor reagents. 3. Synthesis of some 2-substituted 1,4-benzodioxans as selective presynaptic alpha 2-adrenoreceptor antagonists. J Med Chem. 1985 Aug;28(8):1054–1062. doi: 10.1021/jm00146a013. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES